Pharmafile Logo
Pharmafocus logo
Advanced Search

NSCLC

Showing 15 posts of 132 posts found.

Alimta image

NICE rejects Alimta

February 28, 2014
Sales and Marketing Alimta, Cancer, NHS, NICE, NSCLC, lilly, pemetrexed

Eli Lilly is coming to terms with rejection by NICE after the cost watchdog said it would not recommend Alimta …

News
lilly_outside_plaque_1

Lilly drug improves lung cancer survival

February 21, 2014
Research and Development, Sales and Marketing NSCLC, lilly, necitumumab, ramucirumab

News
Roche image

Roche: NICE guidance ‘perverse’

February 4, 2014
Sales and Marketing NHS, NICE, NSCLC, Roche, Tarceva

Roche has poured scorn on NICE’s ‘perverse’ recommendation that its EGFR-TK inhibitor Tarceva should no longer be given to NHS …

News
Pfizer image

Pfizer lung cancer drug suffers late-stage setback

January 28, 2014
Research and Development, Sales and Marketing Cancer, NSCLC, Pfizer, Roche, Tarceva, dacomitinib

An experimental cancer drug developed by Pfizer has failed in two separate Phase III clinical studies. Dacomitinib is a tyrosine …

News

GSK has Tafinlar ‘breakthrough’

January 15, 2014
Sales and Marketing Cancer, FDA, GSK, NSCLC, Tafinlar

GlaxoSmithKline is on a roll, with its cancer drug Tafinlar given breakthrough therapy designation by the FDA in lung cancer …

News

New online tool to hear lung cancer patients’ stories

October 29, 2013
Medical Communications, Sales and Marketing Boehringer, NSCLC, glcc, lung cancer

The Global Lung Cancer Coalition and Boehringer Ingelheim have teamed-up to increase awareness of the challenges facing individuals and families …

News
AstraZeneca imge

AZ begins late-stage trial of new cancer drug

October 22, 2013
Research and Development, Sales and Marketing AstraZeneca, Cancer, NSCLC, selumetinib

AstraZeneca has begun a Phase III study for its investigational lung cancer pill selumetinib in patients with a genetic sub-type …

News
boehringer image

Boehringer cancer drug impresses

October 1, 2013
Research and Development, Sales and Marketing Boehringer, NSCLC, nintedanib

Boehringer Ingelheim has shown off its impressive oncology treatment nintedanib at the European Cancer Congress (ECC) in Amsterdam. The oral triple …

News
Roche image

Roche cancer treatment shows promise

September 30, 2013
Sales and Marketing MPDL3280A, Merck Serono, NSCLC, Roche

An early-stage oncology treatment has shown encouraging results in smokers with lung cancer, Roche has said in a presentation at …

News
Xalkori image

NICE: final ‘no’ for Xalkori

September 25, 2013
Sales and Marketing NICE, NSCLC, Pfizer, Xalkori

Pfizer’s worst fears have been confirmed today by NICE, which has rejected its new lung cancer drug Xalkori because of …

News
Lilly image

Phoenix from the flames for Lilly cancer drug

August 14, 2013
Research and Development, Sales and Marketing NSCLC, lilly, lung cancer, necitumumab

A drug that once looked doomed to fail has shocked analysts by helping late-stage lung cancer patients live longer. Necitumumab …

News
Boehringer image

NSCLC lift for Boehringer

June 4, 2013
Research and Development, Sales and Marketing Boehringer, NSCLC

Boehringer’s pipeline has been boosted with the news that its investigational oral triple angiokinase inhibitor nintedanib plus chemotherapy, extends the …

News

Promising signs for Novartis’ lung cancer drug

June 4, 2013
Sales and Marketing ALK+, ASCO, LDK378, NSCLC, Novartis

Targeted lung cancer treatment LDK378 has been shown to help patients with the ALK+ gene mutation in a phase I trial.Novartis’ drug …

News

Merck KGaA pipeline hit

December 21, 2012
Research and Development, Sales and Marketing Cancer, Merck KGaA, NSCLC, pipeline

Merck KGaA’s pipeline has been dented by the ‘disappointing’ late-stage failure of Stimuvax in a programme with non-small cell lung …

News

Boehringer submits new lung cancer drug

September 20, 2012
Research and Development, Sales and Marketing Boehringer, NSCLC, Roche, Tarceva, afatinib

Boehringer Ingelheim has filed its new lung cancer drug with the EMA. Afatinib is the latest targeted therapy for lung …

News

Latest content

OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

May 24, 2024

Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies

May 24, 2024

BioGen to acquire Human Immunology Biosciences for $1.15bn

May 23, 2024

Merck to acquire Mirus Bio for $600m

May 23, 2024

Rare disease clinical trials: the urgent need for patients to be heard

May 22, 2024